Incretin-Based Therapies: Revisiting Their Mode of Action.
作者信息
Layden Brian T, Wicksteed Barton, Mauvais-Jarvis Franck
机构信息
Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois 60612.
Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.
出版信息
Endocrinology. 2017 Jun 1;158(6):1560-1563. doi: 10.1210/en.2017-00252.
Abstract
摘要
相似文献
1
Incretin-Based Therapies: Revisiting Their Mode of Action.基于肠促胰岛素的疗法：重新审视其作用模式。
Endocrinology. 2017 Jun 1;158(6):1560-1563. doi: 10.1210/en.2017-00252.
2
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.胰高血糖素样肽-1激动剂和二肽基肽酶IV抑制剂。
Handb Exp Pharmacol. 2011(203):53-74. doi: 10.1007/978-3-642-17214-4_3.
3
Recent advances in incretin-based therapies.基于肠促胰岛素的治疗方法的最新进展。
Clin Endocrinol (Oxf). 2012 Oct;77(4):489-99. doi: 10.1111/j.1365-2265.2012.04483.x.
4
Isseki nichō (one stone, two birds): a dual incretin receptor agonist for type 2 diabetes.一石二鸟：一种用于2型糖尿病的双重肠促胰岛素受体激动剂。
Lancet Diabetes Endocrinol. 2022 Sep;10(9):610-611. doi: 10.1016/S2213-8587(22)00193-0. Epub 2022 Jul 30.
5
Incretin-based therapies: viewpoints on the way to consensus.基于肠促胰岛素的疗法：迈向共识之路的观点
Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S223-31. doi: 10.2337/dc09-S315.
6
Diabetes: No increased risk of heart failure with incretin-based drugs.糖尿病：使用肠促胰岛素类药物不会增加心力衰竭风险。
Nat Rev Cardiol. 2016 May;13(5):248. doi: 10.1038/nrcardio.2016.55. Epub 2016 Apr 7.
7
Diabetes: Incretin mimetics and insulin - closing the gap to normoglycaemia.糖尿病：肠促胰岛素类似物与胰岛素——缩小与正常血糖之间的差距
Nat Rev Endocrinol. 2016 Nov 10;12(12):689-690. doi: 10.1038/nrendo.2016.180.
8
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.区分肠促胰岛素治疗：2 型糖尿病的多靶点方法。
J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21.
9
The safety of incretin based drugs.基于肠促胰岛素的药物的安全性。
BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779.
10
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.基于肠促胰岛素的2型糖尿病治疗：胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂
Diabetes Obes Metab. 2007 Sep;9 Suppl 1:23-31. doi: 10.1111/j.1463-1326.2007.00765.x.
引用本文的文献
1
Gut Microbiota: FFAR Reaching Effects on Islets.肠道微生物群：FFAR 对胰岛的影响
Endocrinology. 2018 Jun 1;159(6):2495-2505. doi: 10.1210/en.2018-00296.
本文引用的文献
1
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.肠促胰岛素疗法不会增加年轻雄性小鼠的β细胞量或改变胰腺组织学。
Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.
2
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.胰高血糖素样肽-1 受体激动剂（胰腺炎、胰腺癌和胆石症）的安全性问题：来自随机对照试验的数据。
Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926. Epub 2017 Jun 20.
3
β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions.β-arrestin-2 是生理和病理条件下胰腺 β 细胞功能的重要调节剂。
Nat Commun. 2017 Feb 1;8:14295. doi: 10.1038/ncomms14295.
4
GPCR desensitization: Acute and prolonged phases.G 蛋白偶联受体脱敏：急性和持续阶段。
Cell Signal. 2018 Jan;41:9-16. doi: 10.1016/j.cellsig.2017.01.024. Epub 2017 Jan 28.
5
A Pluridimensional View of Biased Agonism.偏向性激动作用的多维度视角
Mol Pharmacol. 2016 Nov;90(5):587-595. doi: 10.1124/mol.116.105940. Epub 2016 Sep 16.
6
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.目前用于 2 型糖尿病的药物的药理学和治疗意义。
Nat Rev Endocrinol. 2016 Oct;12(10):566-92. doi: 10.1038/nrendo.2016.86. Epub 2016 Jun 24.
7
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.基于肠促胰岛素的药物与胰腺癌风险：国际多中心队列研究
BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581.
8
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.肠促胰岛素疗法：强调胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂作用模式的共同特征与差异
Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591. Epub 2016 Jan 5.
9
β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.β-抑制蛋白在游离脂肪酸受体1上的募集及偏向性激动作用
J Biol Chem. 2015 Aug 21;290(34):21131-21140. doi: 10.1074/jbc.M115.644450. Epub 2015 Jul 8.
10
Human β-cell proliferation and intracellular signaling: part 3.人类β细胞增殖与细胞内信号传导：第3部分。
Diabetes. 2015 Jun;64(6):1872-85. doi: 10.2337/db14-1843.
Zotero 插件